Dr. Chitalia is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
110 Irving St NW
Washington, DC 20010Phone+1 202-877-6998
Education & Training
- Icahn School of Medicine at Mount Sinai/Mount Sinai HospitalFellowship, Hospice and Palliative Medicine, 2013 - 2014
- MedStar Health/Georgetown University HospitalResidency, Internal Medicine, 2010 - 2013
- Tufts University School of MedicineClass of 2010
Certifications & Licensure
- MD State Medical License 2021 - 2026
- DC State Medical License 2010 - 2024
- NY State Medical License 2013 - 2015
- VA State Medical License 2010 - 2014
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Hospice and Palliative Medicine
- American Board of Internal Medicine Medical Oncology
Publications & Presentations
PubMed
- 9 citationsHematologic safety of palbociclib in combination with endocrine therapy in patients with benign ethnic neutropenia and advanced breast cancer.Filipa Lynce, Matthew Blackburn, Rebecca Zhuo, Christopher Gallagher, Olwen Hahn
Cancer. 2021-10-01 - 48 citationsEvaluating radiotherapy options in breast cancer: Does intraoperative radiotherapy represent the most cost-efficacious option?Chirag Shah, Shahed N. Badiyan, Shariq Khwaja, Hardeepak Shah, Ami Chitalia
Clinical Breast Cancer. 2014-04-01 - 3 citationsAdjuvant nivolumab, capecitabine or the combination in patients with residual triple-negative breast cancer: the OXEL randomized phase II study.Filipa Lynce, Candace Mainor, Renee N Donahue, Xue Geng, Greg Jones
Nature Communications. 2024-03-27
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: